Stevens M, Maire CL, Chou N, Murakami MA*, Knoff D, Kikuchi Y, Kimmerling, RJ, Liu H, Haidar S, Calistri NL, Cermak N, Olcum S, Cordero N, Idbaih A, Wen PY, Weinstock DM^, Ligon KL^, Manalis S^. Precise measurement of single cancer cell mass accumulation predicts drug susceptibility. ^equal contribution Nat Biotech 2016;34;1161-67.
http://www.nature.com/nbt/journal/v34/n11/full/nbt.3697.html
Jacobson CA*, Kopp N, Layer JV, Redd RA, Tschuri S, Haebe S, van Bodgeom D*, Bird L*, Christie AL*, Christodoulou A*, Conway A, Tivey T*, Zapf T, Dararia D, Zimber-Strobl U, Rodig SJ, Weigert O^*, Weinstock DM^. HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma. Blood 2016;128;2517-26
http://www.bloodjournal.org/content/early/2016/10/14/blood-2016-04-711176?sso-checked=true
Morgan EA*, Sweeney MP, Tomoka T, Kopp N, Gusenleitner D, Redd RA, Carey CD, Masamba L, Kamiza S, Pinkus GS, Neuberg DS, Rodig SJ, Milner DA, Weinstock DM. Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities. Blood Advances 2016;1;84-92
http://www.bloodadvances.org/content/1/1/84?sso-checked=true
Jurinovic V, Kridel R, Staiger AM, Szczepanowski M, Horn H, Dreyling, MH, Rosenwald A, Ott G, Klapper W, Zelenetz AD, Barr PM, Friedberg JW, Ansell S, Sehn LH, Connors JM, Gascoyne RD, Hiddemann W, Unterhalt M, Weinstock DM, Weigert O*. Prospective Clinicogenetic Risk Models To Predict Early Progression of Follicular Lymphoma after First-Line Immunochemotherapy. Blood 2016;128:1112-20.
http://www.bloodjournal.org.ezp-prod1.hul.harvard.edu/content/128/8/1112.long?sso-checked=true
Cermak N, Olcum S, Delgado FF, Wasserman SC, Payer KR, Ogawa M, Kimmerling RJ, Stevens MM, Murakami MA*, Kikuchi Y, Sandikci, Weinstock DM, Manalis SR. High-throughput growth measurements on single cells via serial microfluidic mass sensor arrays. Nat Biotech 2016;34;1052-59
http://www.nature.com/nbt/journal/v34/n10/full/nbt.3666.html
Melchardt T, Hufnagl C, Weinstock DM, Kopp N, Neureiter D, Trankenschuh W, Hackl H, Weiss L, Rinnerthaler G, Hartmann TN, Greil R, Weigert O*, Egle E. Clonal evolution in relapsed and refractory diffuse large B cell lymphoma is characterized by high dynamics of subclones. Oncotarget [ePub ahead of print: 6/6/16].
Louissaint A*, Schafernak K, Geyer J, Kovach AEE, Ghandi M, Gratzinger D, Roth CG, Paxton CN, Kim S, Namgyal C, Morgan EA, Neuberg DS, South S, Harris MH, Hasserjian RP, Hochberg EP, Garraway LA, Harris NL, Weinstock DM. Pediatric-Type Nodal Follicular Lymphoma is a Biologically Distinct Variant of Lymphoma in Children and Adults With Frequent MAP Kinase Pathway Mutations. Blood 2016;128;1093-1100.
http://www.bloodjournal.org/content/early/2016/06/17/blood-2015-12-682591
Melchardt T, Hufnagl C, Weinstock DM, Kopp N, Neureiter D, Tränkenschuh W, Hackl H, Weiss L, Rinnerthaler G, Hartmann TN, Greil R, Weigert O, Egle E. Clonal evolution in relapsed and refractory diffuse large B cell lymphoma is characterized by high dynamics of subclones. Oncotarget [ePub ahead of print: 6/6/16].
Choi YE, Meghani K, Brault ME, Leclerc L, He YJ, Day TA, Elias KM, Drapkin R, Weinstock DM, Dao F, Shih KK, Matulonis U, Levine DA, Konstantinopoulos PA, Chowdhury D. Platinum and PARP inhibitor resistance due to overexpression of MicroRNA-622 in BRCA1-mutant ovarian cancer. Cell Rep 2016;14:429-39.
http://www.cell.com/cell-reports/abstract/S2211-1247(15)01487-4
Chapuy B, Cheng H, Watahiki A, Ducar MD, Tan Y, Chen L, Roemer MG, Ouyang J, Christie AL, Zhang L, Gusenleitner D, Abo RP, Farinha P, von Bonin F, Thorner AR, Sun HH, Gascoyne RD, Pinkus GS, van Hummelen P, Wulf GG, Aster JC, Weinstock DM, Monti S, Rodig SJ, Wang Y, Shipp MA. Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biologic heterogeneity of the disease. Blood 2016;127:2203-13.
http://www.bloodjournal.org/content/127/18/2203.long?sso-checked=true
Monterzhadat V, Weinstock DM^, Lo A^. Buying cures versus renting health: Financing healthcare via consumer healthcare loans. ^equal contribution Sci Transl Med 2016 Feb 24;8(327):327ps6.
http://stm.sciencemag.org/content/8/327/327ps6.short
Bernasconi-Elias P, Hu T, Jenkins D, Firestone B, Gans S, Kurth E, Capodieci P, Deplazes-Lauber J, Petropoulos K, Thiel P, Ponsel D, Hee Choi S, LeMotte P, London A, Goetcshkes M, Nolin E, Jones MD, Slocum K, Kluk MJ, Weinstock DM, Christodoulou A, Weinberg O, Jaehrling J, Ettenberg SA, Buckler A, Blacklow SC, Aster JC, Fryer CJ. Characterization of activating mutations of NOTCH3 in T cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies. Oncogene 2016 [ePub ahead of print: 5/9/16].
http://www.nature.com/onc/journal/vaop/ncurrent/full/onc2016133a.html
Townsend EC*, Murakami MA*, Christodoulou A, Christie AL, Koester J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu S-C, Plana O, Montero J, Stevenson KE, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf N, LaCasce AS, Lees E, Li L, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY*, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli M, Ritz J, Brown M, Long H, Aster JC, Shipp M, Griffin JD, Weinstock DM. The Public Repository of Xenografts (PRoXe) enables discovery and randomized phase II-like trials in mice. Cancer Cell 2016;29:574-86.
http://www.sciencedirect.com/science/article/pii/S1535610816302689
Wu H, Wang A, Qi Z, Li X, Chen C, Yu K, Zou F, Hu C, Wang W, Zhao Z, Wu J, Liu J, Liu X, Wang L, Wang W, Zhang S, Stone RM, Galinsky IA, Griffin JD, Weinstock D, Christodoulou A, Wang H, Shen Y, Zhai Z, Weisberg EL, Liu J, Liu Q. Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML. Leukemia 2016 [ePub ahead of print: 6/10/16].
http://www.nature.com/leu/journal/vaop/ncurrent/full/leu2016151a.html